Patents Assigned to Cothera BioScience, Inc.
  • Combination therapies for treating cancers
    Patent number: 12076399
    Abstract: Provided are combination therapies and related compositions and methods for treating cancers, including epithelial tumors, which include a combination of at least two agents such as an epidermal growth factor receptor (EGFR) inhibitor, a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and a cyclin dependent kinase (CDK) 4/6 inhibitor.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: September 3, 2024
    Assignee: Cothera Bioscience, Inc.
    Inventors: Yihong Zhang, Wang Wei, Yiyou Chen
  • Polymorphic form of TG02 for treating cancer
    Patent number: 12043630
    Abstract: The present disclosure provides crystalline polymorphic forms of TG02 free base and TG02 acid addition salts, pharmaceutical compositions comprising crystalline polymorphic forms of TG02 free base and TG02 acid addition salts, and methods of treating cancer and other diseases in a patient with crystalline polymorphic forms of TG02 free base and TG02 acid addition salts.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 23, 2024
    Assignee: Cothera Bioscience, Inc.
    Inventors: Robert K. Mansfield, Tracy Parrott
  • COMBINATION THERAPY FOR CANCERS WITH KRAS MUTATION
    Publication number: 20240058339
    Abstract: It relates to a combination therapy for treating cancer with KRAS mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor, (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor, and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Application
    Filed: October 8, 2020
    Publication date: February 22, 2024
    Applicant: COTHERA BIOSCIENCE, INC.
    Inventors: Yiyou CHEN, Chun JIANG
  • COMBINATION THERAPY FOR CANCERS WITH BRAF MUTATION
    Publication number: 20240059778
    Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Application
    Filed: July 24, 2023
    Publication date: February 22, 2024
    Applicant: COTHERA BIOSCIENCE, INC.
    Inventors: Yiyou CHEN, Chun JIANG
  • Treatment of cancer with TG02
    Patent number: 11865116
    Abstract: The present disclosure provides therapeutic methods of treating a cancer patient with TG02 and a second therapeutic agent, e.g., TG02 and an immune checkpoint inhibitor, TG02 and a COX-2 inhibitor, or TG02 and an immune checkpoint inhibitor and a COX-2 inhibitor.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 9, 2024
    Assignee: COTHERA BIOSCIENCE, INC.
    Inventors: Thomas M. Estok, Eckard Weber, Tracy Lee Lawhon
  • COMBINATION THERAPY FOR CANCERS WITH KRAS MUTATION
    Publication number: 20230310436
    Abstract: Provided is a combination therapy for treating cancer with KRAS mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor, (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor, and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Application
    Filed: October 8, 2020
    Publication date: October 5, 2023
    Applicant: COTHERA BIOSCIENCE, INC.
    Inventors: Yiyou CHEN, Chun JIANG
  • Combination therapy for cancers with BRAF mutation
    Patent number: 11753476
    Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: September 12, 2023
    Assignee: Cothera BioScience, Inc.
    Inventors: Yiyou Chen, Chun Jiang
  • COMBINATION THERAPY FOR CANCERS WITH BRAF MUTATION
    Publication number: 20210179718
    Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 17, 2021
    Applicant: Cothera BioScience, Inc.
    Inventors: Yiyou CHEN, Chun JIANG